Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > REPL Replimune > Detailed Quotes

REPL Replimune

17.630
-0.060-0.34%
Close 10/05 16:00 ET
17.6300.0000.00%
Post Mkt Price 10/05 16:02 ET
High
17.800
Open
17.400
Turnover
2.69M
Low
17.090
Pre Close
17.690
Volume
152.98K
Market Cap
869.28M
P/E(TTM)
Loss
52wk High
35.930
Shares
49.31M
P/E(Static)
Loss
52wk Low
13.050
Float Cap
532.11M
Bid/Ask %
0.00%
Historical High
54.850
Shs Float
30.18M
Volume Ratio
0.65
Historical Low
8.580
Dividend TTM
--
Div Yield TTM
--
P/B
2.12
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.51%
Amplitude
4.01%
Avg Price
17.555
Lot Size
1
Float Cap
532.11M
Bid/Ask %
0.00%
Historical High
54.850
Shs Float
30.18M
Volume Ratio
0.65
Historical Low
8.580
Dividend TTM
--
P/B
2.12
Dividend LFY
--
Turnover Ratio
0.51%
Amplitude
4.01%
Avg Price
17.555
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
CEO: Mr. Philip Astley-Sparke
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...